MedTrace Logo

Potential Role of Gum Arabic as Immunomodulatory Agent Among COVID 19 Patients

NCT04381871 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2020-05-12

No results posted yet for this study

Summary

To study the efficacy of Gum Arabic as an immuno modulator and anti-inflammatory agent among COVID 19 seropositive patients..Half of participants will receive Gum Arabic and the other half will receive placebo

Conditions

  • COVID 19

Interventions

DIETARY_SUPPLEMENT

Acacia Senegal

Oral Digestion of Gum Arabic to be consumed early morning on daily basis for 4weeks

DIETARY_SUPPLEMENT

Pectin

Oral Digestion of Pectin to be consumed early morning on daily basis for 12 weeks

Sponsors & Collaborators

  • University of Khartoum

    collaborator OTHER

  • Al-Neelain University

    lead OTHER

Principal Investigators

  • Mustafa KM Nimeiri, MD · Al Neelain University, Faculty of Medicine

  • Moawia M Mukhtar, PhD · University of Khartom , Institute of Endemic Diseases

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2020-08-01
Completion
2020-09-01

Countries

  • Sudan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04381871 on ClinicalTrials.gov